CEA, EpCAM, αvβ6 and uPAR Expression in Rectal Cancer Patients with a Pathological Complete Response after Neoadjuvant Therapy
Rectal cancer patients with a complete response after neoadjuvant therapy can be monitored with a watch-and-wait strategy. However, regrowth rates indicate that identification of patients with a pathological complete response (pCR) remains challenging. Targeted near-infrared fluorescence endoscopy i...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-03-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/11/3/516 |
| _version_ | 1827697672866234368 |
|---|---|
| author | Daan Linders Marion Deken Maxime van der Valk Willemieke Tummers Shadhvi Bhairosingh Dennis Schaap Gesina van Lijnschoten Elham Zonoobi Peter Kuppen Cornelis van de Velde Alexander Vahrmeijer Arantza Farina Sarasqueta Cornelis Sier Denise Hilling |
| author_facet | Daan Linders Marion Deken Maxime van der Valk Willemieke Tummers Shadhvi Bhairosingh Dennis Schaap Gesina van Lijnschoten Elham Zonoobi Peter Kuppen Cornelis van de Velde Alexander Vahrmeijer Arantza Farina Sarasqueta Cornelis Sier Denise Hilling |
| author_sort | Daan Linders |
| collection | DOAJ |
| description | Rectal cancer patients with a complete response after neoadjuvant therapy can be monitored with a watch-and-wait strategy. However, regrowth rates indicate that identification of patients with a pathological complete response (pCR) remains challenging. Targeted near-infrared fluorescence endoscopy is a potential tool to improve response evaluation. Promising tumor targets include carcinoembryonic antigen (CEA), epithelial cell adhesion molecule (EpCAM), integrin αvβ6, and urokinase-type plasminogen activator receptor (uPAR). To investigate the applicability of these targets, we analyzed protein expression by immunohistochemistry and quantified these by a total immunostaining score (TIS) in tissue of rectal cancer patients with a pCR. CEA, EpCAM, αvβ6, and uPAR expression in the diagnostic biopsy was high (TIS > 6) in, respectively, 100%, 100%, 33%, and 46% of cases. CEA and EpCAM expressions were significantly higher in the diagnostic biopsy compared with the corresponding tumor bed (<i>p</i> < 0.01). CEA, EpCAM, αvβ6, and uPAR expressions were low (TIS < 6) in the tumor bed in, respectively, 93%, 95%, 85%, and 62.5% of cases. Immunohistochemical evaluation shows that CEA and EpCAM could be suitable targets for response evaluation after neoadjuvant treatment, since expression of these targets in the primary tumor bed is low compared with the diagnostic biopsy and adjacent pre-existent rectal mucosa in more than 90% of patients with a pCR. |
| first_indexed | 2024-03-10T13:14:09Z |
| format | Article |
| id | doaj.art-11186ba4a95444b6aedc789f8d7454ad |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-10T13:14:09Z |
| publishDate | 2021-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-11186ba4a95444b6aedc789f8d7454ad2023-11-21T10:28:44ZengMDPI AGDiagnostics2075-44182021-03-0111351610.3390/diagnostics11030516CEA, EpCAM, αvβ6 and uPAR Expression in Rectal Cancer Patients with a Pathological Complete Response after Neoadjuvant TherapyDaan Linders0Marion Deken1Maxime van der Valk2Willemieke Tummers3Shadhvi Bhairosingh4Dennis Schaap5Gesina van Lijnschoten6Elham Zonoobi7Peter Kuppen8Cornelis van de Velde9Alexander Vahrmeijer10Arantza Farina Sarasqueta11Cornelis Sier12Denise Hilling13Department of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The NetherlandsDepartment of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The NetherlandsDepartment of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The NetherlandsDepartment of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The NetherlandsDepartment of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The NetherlandsDepartment of Surgery, Catharina Hospital, 5623 EJ Eindhoven, The NetherlandsLaboratory of Pathology, Stichting Pathology and Medical Microbiology, 5623 EJ Eindhoven, The NetherlandsEdinburgh Molecular Imaging Ltd., Edinburgh EH16 4UX, UKDepartment of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The NetherlandsDepartment of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The NetherlandsDepartment of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The NetherlandsDepartment of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The NetherlandsDepartment of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The NetherlandsDepartment of Surgery, Leiden University Medical Center, 2333 ZA Leiden, The NetherlandsRectal cancer patients with a complete response after neoadjuvant therapy can be monitored with a watch-and-wait strategy. However, regrowth rates indicate that identification of patients with a pathological complete response (pCR) remains challenging. Targeted near-infrared fluorescence endoscopy is a potential tool to improve response evaluation. Promising tumor targets include carcinoembryonic antigen (CEA), epithelial cell adhesion molecule (EpCAM), integrin αvβ6, and urokinase-type plasminogen activator receptor (uPAR). To investigate the applicability of these targets, we analyzed protein expression by immunohistochemistry and quantified these by a total immunostaining score (TIS) in tissue of rectal cancer patients with a pCR. CEA, EpCAM, αvβ6, and uPAR expression in the diagnostic biopsy was high (TIS > 6) in, respectively, 100%, 100%, 33%, and 46% of cases. CEA and EpCAM expressions were significantly higher in the diagnostic biopsy compared with the corresponding tumor bed (<i>p</i> < 0.01). CEA, EpCAM, αvβ6, and uPAR expressions were low (TIS < 6) in the tumor bed in, respectively, 93%, 95%, 85%, and 62.5% of cases. Immunohistochemical evaluation shows that CEA and EpCAM could be suitable targets for response evaluation after neoadjuvant treatment, since expression of these targets in the primary tumor bed is low compared with the diagnostic biopsy and adjacent pre-existent rectal mucosa in more than 90% of patients with a pCR.https://www.mdpi.com/2075-4418/11/3/516CEAEpCAMαvβ6uPARfluorescence imagingcomplete response |
| spellingShingle | Daan Linders Marion Deken Maxime van der Valk Willemieke Tummers Shadhvi Bhairosingh Dennis Schaap Gesina van Lijnschoten Elham Zonoobi Peter Kuppen Cornelis van de Velde Alexander Vahrmeijer Arantza Farina Sarasqueta Cornelis Sier Denise Hilling CEA, EpCAM, αvβ6 and uPAR Expression in Rectal Cancer Patients with a Pathological Complete Response after Neoadjuvant Therapy Diagnostics CEA EpCAM αvβ6 uPAR fluorescence imaging complete response |
| title | CEA, EpCAM, αvβ6 and uPAR Expression in Rectal Cancer Patients with a Pathological Complete Response after Neoadjuvant Therapy |
| title_full | CEA, EpCAM, αvβ6 and uPAR Expression in Rectal Cancer Patients with a Pathological Complete Response after Neoadjuvant Therapy |
| title_fullStr | CEA, EpCAM, αvβ6 and uPAR Expression in Rectal Cancer Patients with a Pathological Complete Response after Neoadjuvant Therapy |
| title_full_unstemmed | CEA, EpCAM, αvβ6 and uPAR Expression in Rectal Cancer Patients with a Pathological Complete Response after Neoadjuvant Therapy |
| title_short | CEA, EpCAM, αvβ6 and uPAR Expression in Rectal Cancer Patients with a Pathological Complete Response after Neoadjuvant Therapy |
| title_sort | cea epcam αvβ6 and upar expression in rectal cancer patients with a pathological complete response after neoadjuvant therapy |
| topic | CEA EpCAM αvβ6 uPAR fluorescence imaging complete response |
| url | https://www.mdpi.com/2075-4418/11/3/516 |
| work_keys_str_mv | AT daanlinders ceaepcamavb6anduparexpressioninrectalcancerpatientswithapathologicalcompleteresponseafterneoadjuvanttherapy AT mariondeken ceaepcamavb6anduparexpressioninrectalcancerpatientswithapathologicalcompleteresponseafterneoadjuvanttherapy AT maximevandervalk ceaepcamavb6anduparexpressioninrectalcancerpatientswithapathologicalcompleteresponseafterneoadjuvanttherapy AT willemieketummers ceaepcamavb6anduparexpressioninrectalcancerpatientswithapathologicalcompleteresponseafterneoadjuvanttherapy AT shadhvibhairosingh ceaepcamavb6anduparexpressioninrectalcancerpatientswithapathologicalcompleteresponseafterneoadjuvanttherapy AT dennisschaap ceaepcamavb6anduparexpressioninrectalcancerpatientswithapathologicalcompleteresponseafterneoadjuvanttherapy AT gesinavanlijnschoten ceaepcamavb6anduparexpressioninrectalcancerpatientswithapathologicalcompleteresponseafterneoadjuvanttherapy AT elhamzonoobi ceaepcamavb6anduparexpressioninrectalcancerpatientswithapathologicalcompleteresponseafterneoadjuvanttherapy AT peterkuppen ceaepcamavb6anduparexpressioninrectalcancerpatientswithapathologicalcompleteresponseafterneoadjuvanttherapy AT cornelisvandevelde ceaepcamavb6anduparexpressioninrectalcancerpatientswithapathologicalcompleteresponseafterneoadjuvanttherapy AT alexandervahrmeijer ceaepcamavb6anduparexpressioninrectalcancerpatientswithapathologicalcompleteresponseafterneoadjuvanttherapy AT arantzafarinasarasqueta ceaepcamavb6anduparexpressioninrectalcancerpatientswithapathologicalcompleteresponseafterneoadjuvanttherapy AT cornelissier ceaepcamavb6anduparexpressioninrectalcancerpatientswithapathologicalcompleteresponseafterneoadjuvanttherapy AT denisehilling ceaepcamavb6anduparexpressioninrectalcancerpatientswithapathologicalcompleteresponseafterneoadjuvanttherapy |